Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic

被引:39
|
作者
Mellinger, Jessica L. [1 ]
Winder, Gerald Scott [2 ,7 ]
Fernandez, Anne C. [2 ,3 ]
Klevering, Kristin [3 ,4 ]
Johnson, Amanda [1 ]
Asefah, Haila [1 ]
Figueroa, Mary [5 ]
Buchanan, Jack [6 ]
Blow, Fred [2 ,3 ]
Lok, Anna S. F. [1 ]
机构
[1] Michigan Med, Dept Internal Med, Ann Arbor, MI USA
[2] Michigan Med, Dept Psychiat, Ann Arbor, MI USA
[3] Univ Michigan, Addict Treatment Serv, Michigan Med, Ann Arbor, MI 48109 USA
[4] Michigan Med, Dept Social Work, Ann Arbor, MI USA
[5] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Med Sch, Ann Arbor, MI USA
[7] Michigan Med, Dept Surg, Ann Arbor, MI USA
关键词
Alcoholic cirrhosis; Psychiatry; Addiction; Alcohol use disorder; Quality; VALIDATION; DISORDER;
D O I
10.1016/j.jsat.2021.108396
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Alcohol cessation improves mortality in alcohol-associated liver disease (ALD), but access to treatment is limited. To address this gap, implementation and early feasibility and outcomes of a multidisciplinary ALD clinic are described. Methods: The clinic comprised a hepatologist, psychiatrist, psychologist, nurse, and social worker. Patients included those with alcohol-associated cirrhosis or acute alcoholic hepatitis who were not in the transplant evaluation process, who had less than 6 months' sobriety and willingness to engage in alcohol use treatment. Psychosocial metrics in addition to routine hepatic function labs were collected. Treatment plans were tailored based on patient preferences and needs after multidisciplinary discussion. Results: 89 patients were referred from both inpatient and outpatient settings, with 51 seen during the initial year. 38 remained active in clinic (4 died, 6 discharged, 3 moved to transplant clinic). 55% were women, 88% were white, 61% had private insurance. 49% had alcoholic hepatitis. 71% were decompensated. 80% had severe alcohol use disorder (AUD) and 84% had at least 1 comorbid psychiatric or substance use disorder. 63% chose one-on-one AUD treatment, 57% were prescribed relapse prevention medications. Mean MELD-Na score improved from baseline of 14 (SD 6.6) to 11.3 at 6 months (p=0.01). Hospital utilization significantly declined when comparing 6 months before to 6 months after initial visit (emergency department visits: 0.51 to 0.20 per person-month; inpatient admission: 0.34 to 0.14 per person-month; (beta=-0.89, 95% CI-1.18 to -0.60). Conclusions: A multidisciplinary ALD clinic was feasible with encouraging early outcomes. Further research should explore ways to expand this model and increase clinic capacity.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Elevated stearoyl-CoA desaturase 1 activity is associated with alcohol-associated liver disease
    Klepp, T. D.
    Sloan, M. E.
    Soundararajan, Soundarya
    Ramsden, C. E.
    Cinar, R.
    Schwandt, M. L.
    Diazgranados, N.
    Vatsalya, V.
    Ramchandani, V. A.
    ALCOHOL, 2022, 102 : 51 - 57
  • [32] Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action
    Haque, Lamia Y.
    Zuluaga, Paola
    Muga, Robert
    Fuster, Daniel
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2024, 19 (01)
  • [33] Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action
    Lamia Y. Haque
    Paola Zuluaga
    Robert Muga
    Daniel Fuster
    Addiction Science & Clinical Practice, 19
  • [34] The gut microbiome in alcohol use disorder and alcohol-associated liver disease: A systematic review of clinical studies
    Grodin, Erica N.
    Burnette, Elizabeth M.
    Rodriguez, Crystal
    Fulcher, Jennifer A.
    Ray, Lara A.
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 48 (07): : 1221 - 1242
  • [35] Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease
    Addolorato, Giovanni
    Ponziani, Francesca R.
    Dionisi, Tommaso
    Mosoni, Carolina
    Vassallo, Gabriele A.
    Sestito, Luisa
    Petito, Valentina
    Picca, Anna
    Marzetti, Emanuele
    Tarli, Claudia
    Mirijello, Antonio
    Zocco, Maria Assunta
    Lopetuso, Loris R.
    Antonelli, Mariangela
    Rando, Maria M.
    Paroni Sterbini, Francesco
    Posteraro, Brunella
    Sanguinetti, Maurizio
    Gasbarrini, Antonio
    LIVER INTERNATIONAL, 2020, 40 (04) : 878 - 888
  • [36] Origin, Function, and Implications of Intestinal and Hepatic Macrophages in the Pathogenesis of Alcohol-Associated Liver Disease
    Hu, Yifan
    Schnabl, Bernd
    Starkel, Peter
    CELLS, 2025, 14 (03)
  • [37] Smartphone sensor data estimate alcohol craving in a cohort of patients with alcohol-associated liver disease and alcohol use disorder
    Wu, Tiffany
    Sherman, Garrick
    Giorgi, Salvatore
    Thanneeru, Priya
    Ungar, Lyle H.
    Kamath, Patrick S.
    Simonetto, Douglas A.
    Curtis, Brenda L.
    Shah, Vijay H.
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (12)
  • [38] Prior metabolic and bariatric surgery is an independent determinant of severity of decompensation in alcohol-associated liver disease
    Onghena, Louis
    van Nieuwenhove, Yves
    Van Vlierberghe, Hans
    Devisscher, Lindsey
    Raevens, Sarah
    Verhelst, Xavier
    Lefere, Sander
    Geerts, Anja
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (10) : 1440 - 1449
  • [39] The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study
    Yang, Keungmo
    Kim, Sunghwan
    Yang, Hyun
    Wang, Sheng-Min
    Jeong, Bumseok
    Lim, Hyun Kook
    Bae, Si Hyun
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04) : 929 - 942
  • [40] Selection Criteria for Liver Transplantation for Acute Alcohol-Associated Hepatitis
    Goel, Aparna
    Daugherty, Tami
    CLINICS IN LIVER DISEASE, 2021, 25 (03) : 635 - 644